FDA Review Challenges the Deramiocel Evidence Package
FDA briefing materials concluded that Capricor’s HOPE-3 study did not meet its prespecified efficacy endpoints and raised questions about changes in analysis and data interpretation. Capricor disputes the agency’s chronology and interpretation. The event…
